Funding Shortfalls Pressure Small and Rural Hospitals to Delay Essential Data Security Investments; Survey of 187 Small ...

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

Annual General Meeting GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of ...

WASHINGTON, DC / ACCESS Newswire / June 30, 2025 / The not-for-profit Aimed Alliance released a comprehensive new report analyzing how state policies govern step therapy, internal and external appeal ...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPFirst-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy ...

PRO isn’t just digitized data collection. It’s real-time, structured, regulatory-grade intelligence, designed to enhance compliance, cut down queries, and keep patients engaged.Despite operating in a ...

A New Perspective on Addiction RecoveryIn the journey to overcome addiction, one size certainly does not fit all. Every individual faces different challenges, circumstances, and needs. While some ...

Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA ...

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

LUND, SWEDEN / ACCESS Newswire / June 30, 2025 / During June 2025, the number of shares and votes in Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience")has increased as a result of the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...